OncoMatch/Clinical Trials/NCT06734182
Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer
Is NCT06734182 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Envafolimab injections+intravenous Disitamab Vedotin+carboplatin for non-small cell lung cancer.
Treatment: Envafolimab injections+intravenous Disitamab Vedotin+carboplatin — This is a prospective, single-arm, multi-center, phase II clinical study to evaluate the efficacy and safety of Envafolimab injection (PD-L1) combined with Disitamab Vedotin (HER2 ADC) and Carboplatin for resectable, HER2-Mutant, stage II-IIIB, NSCLC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) mutation
HER2 mutations identified by histological specimens
Required: EGFR sensitizing mutation
Participants with known EGFR sensitive mutations
Required: ALK fusion
Participants with known...ALK translocation
Required: KRAS sensitizing mutation
KRAS sensitive mutations
Required: BRAF V600E
BRAF V600E
Required: ROS1 fusion
ROS1 fusions
Required: RET fusion
RET fusions
Required: MET exon 14 alteration
MET exon 14 alterations
Required: MET amplification
MET amplification
Required: NTRK1 fusion
NTRK fusions
Required: NTRK2 fusion
NTRK fusions
Required: NTRK3 fusion
NTRK fusions
Disease stage
Required: Stage II, IIIA, IIIB (AJCC version 9)
Excluded: Stage IIIC
resectable, stage II, IIIA, IIIB (AJCC staging system, version 9) NSCLC; unresectable includes the unresectable defined in the Chinese expert consensus on the multidisciplinary diagnosis and treatment for stage III non-small cell lung cancer (2019), including partial stage IIIA and IIIB and all the stage IIIC
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic antitumor therapy
Previous treatment with systemic antitumor therapy for early NSCLC, including investigational product
Cannot have received: PD-1/PD-L1 agent or drug acting on another targeted T cell receptor
Previous use of PD-1/PD-L1 agent or the drug acting on another targeted T cell receptor (e.g., CTLA-4, OX-40)
Lab requirements
Blood counts
Adequate organ function
Kidney function
Adequate organ function
Liver function
Adequate organ function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify